A
Alvaro Montaño
Researcher at Services Hospital
Publications - 15
Citations - 523
Alvaro Montaño is an academic researcher from Services Hospital. The author has contributed to research in topics: Breast cancer & Internal medicine. The author has an hindex of 4, co-authored 11 publications receiving 335 citations.
Papers
More filters
Journal ArticleDOI
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Sung Bae Kim,Rebecca Dent,Seock-Ah Im,Marc Espié,Sibel Blau,Antoinette R Tan,Steven J Isakoff,Mafalda Oliveira,Cristina Saura,Matthew Wongchenko,Amy V. Kapp,Wai Y. Chan,Stina M. Singel,Daniel J Maslyar,José Baselga,Keun Seok Lee,Hwei Chung Wang,Antoinette R. Tan,Joohyuk Sohn,Michelino De Laurentiis,Laura G. Estévez,Chiun-Sheng Huang,Gilles Romieu,Michel Velez,Rafael Villanueva,Pierfranco Conte,Shaker R. Dakhil,Marc Debled,Antonio Gonzalez Martin,Sara A. Hurvitz,Jee Hyun Kim,Christelle Levy,Pedro Sánchez Rovira,Jae Hong Seo,Vicente Valero,Gregory Vidal,Andrea Wong,Mary Ann K Allison,Robert A. Figlin,David Chan,Shin-Cheh Chen,Yen-Hsun Chen,Melody A. Cobleigh,Filippo de Braud,Luc Dirix,Vincent Hansen,Anne Hardy Bessard,Nicholas Iannotti,Steven J. Isakoff,William E. Lawler,Alvaro Montaño,Mohamad Salkini,Leonard Seigel +52 more
TL;DR: These are the first results supporting AKT-targeted therapy for triple-negative breast cancer and Ipatasertib warrants further investigation for the treatment of triple- negative breast cancer.
Journal ArticleDOI
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Aleix Prat,Cristina Saura,Cristina Saura,Tomás Pascual,Cristina Hernando,Montserrat Muñoz,Laia Paré,Blanca González Farré,Pedro L. Fernández,Patricia Galván,Nuria Chic,Xavier González Farré,Mafalda Oliveira,Mafalda Oliveira,Miguel Gil-Gil,Miriam Arumí,Neus Ferrer,Alvaro Montaño,Yann Izarzugaza,Antonio Llombart-Cussac,Raquel Bratos,Santiago Gonzalez Santiago,Eduardo Martínez,Sergio Hoyos,Beatriz Rojas,Juan Antonio Virizuela,Vanesa Ortega,Rafael López,Pamela Céliz,Eva Ciruelos,Patricia Villagrasa,Joaquín Gavilá +31 more
TL;DR: The results suggest that some patients with high-risk, early stage, hormone receptor-positive, HER2-negative breast cancer could achieve molecular downstaging of their disease with CDK4/6 inhibitor and endocrine therapy.
Journal ArticleDOI
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial.
Eva Ciruelos,Patricia Villagrasa,Tomás Pascual,Mafalda Oliveira,Mafalda Oliveira,Sonia Pernas,Laia Paré,Laia Paré,Santiago Escrivá-de-Romaní,Luis Manso,Barbara Adamo,Eduardo Martínez,Javier Cortes,Silvia Vazquez,Antonia Perelló,I Garau,M Melé,Noelia Martínez,Alvaro Montaño,Begoña Bermejo,Serafin Morales,Maria Jose Echarri,Estela Vega,Blanca Gonzalez-Farre,D. Martinez,Patricia Galván,Jordi Canes,Paolo Nuciforo,Xavier Gonzalez,Aleix Prat,Aleix Prat +30 more
TL;DR: Palbociclib in combination with trastuzumab is safe and exhibits promising survival outcomes in trastizumab pretreated ER-positive/HER2-positive advanced breast cancer with a PAM50 Luminal A or B subtype.
Journal ArticleDOI
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
Alberto Ocaña,M. Gil-Martin,Silvia Antolín,María Atienza,Alvaro Montaño,Nuria Ribelles,Ander Urruticoechea,Alejandro Falcon,Sonia Pernas,Javier Orlando,Juan Carlos Montero,M. J. Escudero,Sara Benito,Rosalia Caballero,Eva Carrasco,Federico Rojo,Atanasio Pandiella,Manuel Ruiz-Borrego +17 more
TL;DR: Dasatinib can be safely combined with trastuzumab and paclitaxel and the combination is active with an ORR of almost 80%.
Journal ArticleDOI
First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study.
Sonia Pernas,Patricia Villagrasa,Ana Vivancos,Maurizio Scaltriti,Jordi Rodon,Jordi Rodon,Octavio Burgues,Paolo Nuciforo,Jordi Canes,Laia Paré,Marta Dueñas,Maria Vidal,Juan Miguel Cejalvo,Antonia Perelló,Antonio Llommbard-Cussac,Joan Dorca,Alvaro Montaño,Tomás Pascual,Mafalda Oliveira,Mafalda Oliveira,Gloria Ribas,Inmaculada Rapado,Aleix Prat,Eva Ciruelos +23 more
TL;DR: The SOLTI-1301 AGATA study as discussed by the authors assessed the feasibility of a multi-institutional molecular screening program to better characterize the genomic landscape of advanced breast cancer and to facilitate patient access to matched-targeted therapies in Spain.